# Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

> **NCT05758389** · PHASE2 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 29 (estimated)

## Conditions studied

- Head and Neck Tumors

## Interventions

- **DRUG:** Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU

## Key facts

- **NCT ID:** NCT05758389
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2025-08-07
- **Final completion:** 2025-12-07
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758389, "Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05758389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*